Along with the details of an ambitious new organization restructuring and strategic product plan, Shire CEO Flemming Ornskov emphasizes talks about the importance of alignment with the customer and the untapped potential from Shire’s expertise in that sweet spot in specialty – rare diseases.
Dr. Flemming Ornskov, just ending his first month as the new CEO of Shire – perhaps the most successful stealth company of all, with a track record for periodically recharging its portfolio in pace with emerging areas of real unmet medical need.
Along with the details of an ambitious new organization restructuring and strategic product plan, Ornskov emphasized his background as a physician pediatrician in relating complex science to the real life world of patients and payers, in the commercial marketplace.
The following is a brief excerpt from our conversation, where he talks about the importance of alignment with the customer and the untapped potential from Shire’s expertise in that sweet spot in specialty – rare diseases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.